What you'll learn in this expert session
Which immunocompromised patients should be given the recombinant (Shingrix) vs the Inactivated (Zostavax)? Prof Cunningham describes how immunocompromised patients fit into 1 of 3 basic categories. Each of these categories warrants a different degree of caution, and each warrants a different approach to vaccination choice.
About the Expert
Prof Tony Cunningham AO
Prof Anthony (Tony) Cunningham AO, FAHMS, MD, FRACP, FRCPA is an infectious diseases physician, clinical virologist and scientist. He is the past Director, Centre for Virus Research at The Westmead Institute for Medical Research (WIMR); Director, Australian Centre for HIV and Hepatitis Virology Research (ACH2); and Professor in the Faculty of Medicine and Health at the University of Sydney.
Prof Cunningham is the lead author of the ‘Vaccines for COVID-19’ paper, commissioned from the Australian Academy of Health and Medical Sciences.

Course curriculum
-
1
How to complete this course
-
Instructions
-
-
2
Shingles Vaccination in the Immunocompromised - Which Option for Which Patient?
-
Summary
-
Video lecture (25 mins)
-
Quiz: test your learning (10 mins)
-
-
3
Document your CPD here
-
CPD Documentation and Reflection Activity Tool
-
-
4
Feedback
-
Please let us know your thoughts
-